Aquestive Therapeutics Reports Third Quarter 2018 Financial Results and Recent Business Highlights
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Aquestive Therapeutics (AQST) PT Raised to $24 at RBC Capital
November 7, 2018 7:09 AM ESTRBC Capital analyst Randall Stanicky raised the price target on Aquestive Therapeutics (NASDAQ: AQST) to $24.00 (from $23.00) while maintaining an Outperform rating following results.
Stanicky said pending Sympazan launch set to pave the way for lead product Libervant next year.
... MoreAquestive Therapeutics Inc. (AQST) Misses Q3 EPS by 16c
November 6, 2018 4:43 PM ESTAquestive Therapeutics Inc. (NASDAQ: AQST) reported Q3 EPS of ($0.64), $0.16 worse than the analyst estimate of ($0.48). Revenue for the quarter came in at $13.3 million versus the consensus estimate of $14.24 million.
As of September 30, 2018, Aquestive's cash and cash equivalents were $64.0 million, as compared to $17.4 million as of... More
